(SOW dee um tetra DEK il SUL fate)
Treatment of small, uncomplicated varicose veins of the lower extremities
Hypersensitivity to sodium tetradecyl sulfate or any component of the formulation; arterial disease, acute thrombophlebitis; valvular or deep vein incompetence, phlebitis migrans, cellulitis, acute infections; bedridden patients; patients with uncontrolled systemic disease such as diabetes, toxic hyperthyroidism, tuberculosis, asthma, neoplasm, sepsis, blood dyscrasias, and acute respiratory or skin diseases; huge superficial veins with wide open communications to deeper veins; allergic conditions; varicosities caused by abdominal and pelvic tumors (unless tumor has been removed)
Sclerosing agent: IV: Test dose: 0.5 mL given several hours prior to administration of larger dose; 0.5-2 mL (preferred maximum: 1 mL) in each vein, maximum: 10 mL per treatment session; 3% solution reserved for large varices
Refer to adult dosing.
No dosage adjustment provided in manufacturer 's labeling.
No dosage adjustment provided in manufacturer 's labeling.
Inject slowly.
Store at controlled room temperature.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intravenous, as sulfate:
Sotradecol: 1% (2 mL); 3% (2 mL) [contains benzyl alcohol]
Incompatible with heparin.
There are no known significant interactions.
Monitor for DVT or PE (up to 4 weeks after injection)
Frequency not defined.
Central nervous system: Headache
Dermatologic: Discoloration at site of injection, sloughing and tissue necrosis following extravasation
Gastrointestinal: Nausea, vomiting
Local: Pain, itching, or ulceration at injection site
Miscellaneous: Allergic reaction (including hives, asthma, hay fever); anaphylactic shock
Concerns related to adverse effects:
- Anaphylaxis: Observe for hypersensitivity/anaphylactic reaction; emergency resuscitation equipment should be available.
- Thromboembolism: Deep vein thrombosis (DVT) and pulmonary embolism (PE) have occurred following treatment.
Disease-related concerns:
- Arteriosclerosis: Use with caution in patients with peripheral arteriosclerosis.
- Thromboangiitis obliterans: Use with caution in patients with thromboangiitis obliterans.
Other warnings/precautions:
- Appropriate use: Valvular and venous competency should be evaluated prior to use.
- Extravasation: Avoid extravasation.
C
Reproduction studies have not been conducted.
Acts by irritation of the vein intimal endothelium and causes thrombosis formation leading to occlusion of the injected vein
- Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
- Patient may experience headache, nausea, vomiting, or skin discoloration at injection site. Have patient report immediately to prescriber skin ulcers, injection site pain, or signs of blood clots (numbness or weakness on one side of the body; pain, redness, tenderness, warmth, or swelling in the arms or legs; change in color of an arm or leg; angina; shortness of breath; fast heartbeat; or coughing up blood) (HCAHPS).
- Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.